Joint Accreditation Statement
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute of Medicine designates this continuing education activity for 5.0 contact hours (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 5.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Upon completion of the 2019-2020 activity, participants should be able to:
- Describe the rationale for common approaches to cancer immunotherapy.
- Identify the appropriate clinical management of immune-related adverse events of immunotherapy agents.
- Implement cancer immunotherapy treatments for skin cancers, lung, genitourinary, head and neck, hematologic cancers, and/or additional solid tumors into clinical practice appropriately.
- Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.
For optimal completion of this program, the attendee will need a computer/laptop with a strong WiFi connection and the ability to stream video.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
View the SITC Meeting Code of Conduct.